ストックスクリーナーアプリを入手
1.87
1.63%
0.03
前日終値:
$1.84
開ける：
$1.85
24時間の取引高:
602.22K
Relative Volume:
0.46
時価総額：
$297.58M
収益：
$10.00M
当期純損益:
$-29.47M
株価収益率:
-9.35
EPS:
-0.2
ネットキャッシュフロー:
$-21.55M
1週間 パフォーマンス:
+3.89%
1か月 パフォーマンス:
-10.95%
6か月 パフォーマンス:
-14.61%
1年 パフォーマンス:
-47.47%
1日の値動き範囲:
$1.81
$1.89
1週間の範囲:
$1.75
$1.89
52週間の値動き範囲:
$1.47
$3.94
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
名前
Mereo Biopharma Group Plc Adr
セクター
電話
4403330237300
住所
ONE CAVENDISH PLACE, LONDON
MREO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
1.87 | 292.80M | 10.00M | -29.47M | -21.55M | -0.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-27 | 開始されました | JP Morgan | Overweight |
| 2024-12-06 | 開始されました | Jefferies | Buy |
| 2024-06-13 | 開始されました | Robert W. Baird | Outperform |
| 2023-10-13 | 再開されました | BTIG Research | Buy |
| 2022-08-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-05-05 | 開始されました | BTIG Research | Buy |
| 2021-04-05 | 開始されました | Needham | Buy |
すべてを表示
Mereo Biopharma Group Plc Adr (MREO) 最新ニュース
Equities Analysts Issue Forecasts for MREO FY2025 Earnings - Defense World
A better buy-in window may exist right now for Mereo Biopharma Group Plc ADR (MREO) - Setenews
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Wall Street analysts’ outlook for Mereo Biopharma Group Plc ADR (MREO) - Setenews
FY2025 EPS Forecast for Mereo BioPharma Group Cut by Analyst - Defense World
Leerink Partnrs Has Negative Forecast for MREO Q4 Earnings - MarketBeat
Leerink Partnrs Issues Negative Forecast for MREO Earnings - Defense World
A new trading data show Mereo Biopharma Group Plc ADR (MREO) is showing positive returns. - setenews.com
[8-K] Mereo BioPharma Group plc Reports Material Event | MREO SEC FilingForm 8-K - Stock Titan
Mereo Biopharma Group Plc ADR (MREO) looking to reclaim success with recent performance - Setenews
Tangible book value per share of Mereo BioPharma Group plc Sponsored ADR – HAN:MAH0 - TradingView
Mereo BioPharma Group plcSponsored ADR (NASDAQ:MREO) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Aberdeen Group plc Has $8.21 Million Stock Position in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Average Rating of “Buy” by Brokerages - Defense World
Mereo Biopharma Group Plc ADR (MREO) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Atle Fund Management AB Has $2.07 Million Stock Position in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
Goldman Sachs Group Inc. Raises Stake in Mereo BioPharma Group plc – Sponsored ADR $MREO - Defense World
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), KalVista Pharmaceuticals (KALV) and Argenx Se (ARGX) - The Globe and Mail
Adage Capital Partners GP L.L.C. Has $3.83 Million Stock Position in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Average Recommendation of “Buy” by Brokerages - Defense World
Frazier Life Sciences Management L.P. Increases Stock Holdings in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - cnhinews.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - FinancialContent
Pomerantz LLP investigates Mereo BioPharma securities fraud claims. - AInvest
JPMorgan Chase & Co. Issues Positive Forecast for Mereo BioPharma Group (NASDAQ:MREO) Stock Price - Defense World
Mereo BioPharma Group plc investigated for securities fraud and unlawful practices. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
FY2026 EPS Estimates for MREO Lifted by Cantor Fitzgerald - Defense World
Oklahoma City NewsThe Oklahoman - Markets Financial Content
Leerink Partnrs Has Negative Outlook for MREO Q3 Earnings - Defense World
Analysts Offer Predictions for MREO Q3 Earnings - Defense World
Mereo BioPharma Group faces securities fraud investigation. - AInvest
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Receives Average Rating of “Buy” from Analysts - Defense World
Mereo BioPharma ADR earnings beat, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Mereo BioPharma Reports Q2 2025 Financial Results and Updates on Setrusumab Phase 3 Studies for Osteogenesis Imperfecta - Quiver Quantitative
Mereo's Setrusumab Phase 3 Trials Hit Key Safety Milestone: Year-End Results Coming for Rare Bone Disease - Stock Titan
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewswire
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail
Pomerantz LLP Investigates Mereo BioPharma Group Securities Fraud Claims. - AInvest
Pomerantz LLP investigates Mereo BioPharma Group securities fraud claims. - AInvest
Mereo BioPharma investigated for potential securities fraud. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPharma Group plc (MREO) And Encourages Shareholders to Connect - ACCESS Newswire
Mereo Biopharma Group Plc Adr (MREO) 財務データ
収益
当期純利益
現金流量
EPS
0.45%
1.13%
大文字化:
|
ボリューム (24 時間):